David A.

David A. is an experienced executive in the field of medical affairs and strategic leadership, currently serving as the VP of Strategy at BostonGene since July 2025. Previously, David held significant roles at Takeda Oncology, including Head of Pipeline, BD & Hematology, where responsibilities encompassed global medical affairs leadership for oncology pipelines, and as Head of Multiple Myeloma, overseeing the disease area portfolio. David's earlier experience includes leadership positions at AbbVie and Pharmacyclics, focusing on brand leadership and medical affairs. Additionally, David contributed to Eli Lilly and Company as Director of Target Generation, where initiatives included novel target identification and R&D portfolio strategy. David obtained an MBA from Duke University and a PhD in Biology from UC San Diego.